Trial Profile

An Exploratory, Open Labelled, Phase IIa Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With Clostridium Difficile-associated Diarrhea (CDAD)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 May 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MGB BP 3 (Primary)
Indications Clostridium difficile infections; Diarrhoea
Focus Adverse reactions; Therapeutic Use
Sponsors MGB Biopharma

Most Recent Events

19 May 2020 According to a MGB Biopharma Media Release, Dr Thomas Louie, clinical professor at the Cumming School of Medicine at the University of Alberta, Calgary (Canada) is the Principal Investigator of the trial
19 May 2020 Results published in MGB Biopharma Media Release
14 Apr 2020 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com